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Abstract: Benign bone tumors are commonly diagnosed and treated. Following tumor removal, the defect in the bone can 
be filled with auto- or allografts, (degradable) bone substitutes or non-degradable polymethylmethacrylate. The ideal sub-
stitute for this purpose should provide immediate structural support and readily incorporate into bone over a short period 
of time. Experimentally, microparticulate allograft has been shown to incorporate quickly in metaphyseal and meta-
diaphyseal cortico-cancellous defects in primates [1]. Using a combination of small allogeneic cortical graft particles (< 
250 μm), bone defects were filled following intralesional excision in 97 consecutive patients with benign and low grade 
malignant tumors and tumor-like conditions of bone. The clinical results and rate of radiographic incorporation and osse-
ous consolidation were recorded and analyzed. These patients underwent 104 procedures in which osseous defects were 
packed with microparticulate allograft. The follow-up was from 23 to 49 months. There were 94 (90.3%) closed defects 
and 10 (9.7%) open defects. The average size of the grafted defect was 42.8 cm
3 (0.48 - 315.0 cm
3). Internal fixation was 
used in 11 of the 104 procedures (10.6 %). Radiographically, incorporation was observed in 91% of patients and consoli-
dation in 60%. There were eleven failures (10.6 %), eight (72 %) due to tumor recurrence. Seven of eight patients with 
tumor recurrence underwent a second resection and grafting procedure that resulted in allograft incorporation and defect 
healing. There were two deep infections requiring debridement with retention of the graft; both resolved with satisfactory 
healing. 
Both incorporation and consolidation were observed in over 90% of patients with a low rate of complications. The use of 
small-particle cortical allograft proved to be an effective alternative to autogenous bone graft in patients with metaphyseal 
and metadiaphyseal surgical bone defects. 
INTRODUCTION 
  Benign bone tumors and tumor-like conditions of bone 
are rather common. After these lesions are surgically re-
moved the defects are usually filled with either an autograft, 
an allograft, a variety of bone substitutes or polymeth-
ylmethacrylate. Ideally, the material selected should be both 
osteoconductive and osteoinductive, it should provide suffi-
cient early mechanical stability, and it should allow the re-
generation of normal bone in a short period of time. 
  Advances in surgical technology, during the latter half of 
the twentieth century, have coincided with an increase in the 
use of new materials and complex surgical procedures for 
bone repair [2-6]. Autogenous bone is still considered to be 
the gold standard for bone grafting. It provides three ele-
ments necessary to generate and maintain bone: scaffolding 
for osteoconduction, growth factors for osteoinduction, and 
progenitor cells for osteogenesis. Cancellous autograft, how-
ever, is in limited supply and its harvesting can result in sig-
nificant donor site morbidity. Allografts, on the other hand, 
may not have similar osteoinductive properties to autografts, 
depending on the way these grafts have been processed. 
Since the means of preparation and storage, and the struc-
tural form of the allograft may significantly affect graft in-
corporation, its use has been associated with mixed clinical  
 
 
*Address correspondence to this author at the Tissue Bank, Department of 
Orthopaedics, University of Miami, Miller School of Medicine, Miami, 
Florida  33101, USA; E-mail: htemple@med.miami.edu 
results. Therefore in the past several years, there has been an 
explosion in the development of bone substitutes, growth 
factors, and combinations of the two that have made their 
way to the medical market [3,4]. Well designed clinical tri-
als, however, have not yet demonstrated their efficacy or 
safety [2]. 
  As the orthopaedic oncologist’s ability to achieve local 
control of bone tumors improves, emphasis is placed on 
healing of the bone cavity to achieve early function [5, 7]. 
For most benign tumors, intralesional curetting and bone 
grafting is the treatment of choice [8]. The materials used to 
achieve this are: autograft, bone substitutes, cement, and 
allograft. 
  The usefulness of autograft is limited by availability and 
donor morbidity. Donor site complications, infection and 
lateral femoral cutaneous nerve injury, as well as structural 
insufficiency that can lead to fracture may result in increased 
patient recovery time, disability, and chronic pain [3]. Fur-
thermore, the residual pain and disability that may result 
from harvesting cancellous iliac crest bone can be relatively 
long-lasting. These problems justify continued efforts to find 
effective bone graft substitutes as alternatives to autografts 
[4, 9]. 
  Biocompatible substitute materials, such as porous hy-
droxyapatite, tricalcium phosphate, etc offer the surgeon 
additional choices in the repair of cavitary long bone defects 
[3, 6]. The ideal composite synthetic grafts should effec-
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(osteoinduction, osteoconduction and progenitor cells) [6]. 
The drawbacks of many substitutes include low biocompati-
bility, poor restorability, inclusion of processed animal com-
ponents, inferior handling characteristics, and cost. In clini-
cal practice, incomplete healing has occurred commonly in 
patients with large lesions [5]. Further investigation, in ani-
mal models, evaluating different defect sizes and biome-
chanical conditions will help to determine the appropriate 
use for these materials [10, 11]. 
  Polymethymethacrylate (PMMA) has been used to fill 
large subchondral defects following removal of giant cell 
tumors.. Once polymerized, PMMA resists axial loading and 
thus provides immediate structural support. Moreover, the 
exothermic reaction during polymerization is thought by 
some to extend the margin of resection. PMMA, however, 
has no biologic activity and cannot remodel in the face of 
changing stresses. Therefore, it is less desirable for the 
treatment of curable lesions when the goal is complete resto-
ration of anatomy and function [12]. 
  Allograft bone has now been used clinically for more 
than 50 years for various orthopaedic indications [13-16]. 
Allografts are available in reasonable quantities and are ver-
satile since shape, contour, and mineral density can be al-
tered and tailored to a particular clinical indication. Allograft 
structure is very important when considering the type of de-
fect and the means by which the graft can be expected to 
incorporate over time. Materials such as DBM (Demineral-
ized Bone Matrix), DFDBA (Demineralized Freeze-Dried 
Bone Allograft), allograft paste, powder, chips, strips and 
putty, all have different mechanical and osteoinductive prop-
erties [17-20]. Osteoinductive properties of allograft bone 
can be altered by many different secondary sterilization 
techniques. Allograft chips, when used to fill acetabular de-
fects in total hip revision surgery, have shown, in micro-
scopic preparations, to incorporate within 3 weeks [14, 19]. 
Massive allografts, incompletely incorporate from the pe-
riphery inward by a process of creeping substitution [21]. 
Unpredictable clinical results have been reported with these 
for a variety of reasons [15, 18]. On the other hand cortical 
microparticulate allograft incorporates rapidly due to ex-
posed inductive proteins from the large trabecular surface 
area and interconnected spaces [1, 9]. Furthermore, due to 
the small particle size, the resorptive phase of bone healing 
is accelerated. 
  Independent of the type of graft used, the size of graft 
particles has an important effect on incorporation [1, 22, 23]. 
Thus, Shapoff, et al. [22] demonstrated increased osteogene-
sis with small particle, freeze-dried bone allograft when 
compared to larger particles. However the studies of 
Syftestad an Urist [23], showed that very small particle sizes 
(under 125 μm) provided an increase in surface area that 
enhanced the generation of mechanically-induced free radi-
cals resulting in increased solubility of bone matrix proteins 
and decreased bone production. 
  Allograft particle size is also related to resistance to shear 
stresses.  In vitro experiments, using morsellised allograft 
bone, have shown that the graft’s mechanical properties im-
prove with increasing normal load and with increasing shear 
strains (strain hardening) [24]. Further studies were needed 
to determine the optimal allograft particle size for filling 
bone defects. These were provided by the experiments on 
non-human primates and were applied to the present clinical 
investigation [1, 7]. 
  Optimal osteoconduction is provided by direct apposition 
between host bone and the implant. The host bone must be 
viable, the host bone/implant interface must be stable and the 
implant needs to have a structure (porosity) that allows new 
bone in-growth. Also important is the fact that optimal in-
corporation of the graft occurs when histocompatibility dif-
ferences are minimized by either matching tissue types or by 
treating the allograft with techniques that reduce immuno-
genicity [13]. Although freezing significantly reduces anti-
genicity and thus the inflammatory response it does not re-
duce it as much as does freeze-drying [7]. Furthermore, al-
though allografts pose a known risk of bacterial contamina-
tion and viral transmission, rigorous tissue screening and 
microbiologic and serologic testing of donor tissue reduce 
these risks to theoretical possibilities [13]. 
  The microparticulate allograft is a mixture of mineralized 
cortical bone particles of a standard combination of sizes 
between 100 and than 250 microns. This provides an optimal 
scaffold for delivering osteoinductive growth factors. This 
preparation has an appropriate 3-dimensional (3-D) structure 
to serve as an osteoconductive matrix for bone-forming cells. 
  The purpose of this study was to evaluate, in a prospec-
tive, consecutive series of patients, the results obtained with 
freeze-dried small-particle cortical allograft as an alternative 
for autogenous bone graft in filling bone defects created by 
tumor ablation. Our hypothesis was that freeze-dried cortical 
microparticulate allografts would induce healing of bone 
defects in a manner similar to autografts. Freeze-dried mi-
croparticulate allografts were chosen because they were 
shown to incorporate faster than frozen microparticulate al-
lografts [7]. Likewise cortical bone particulate allografts 
with particle sizes from 300 to 90  were shown experimen-
tally to produce healing of bone defects in a manner and rate 
that was identical to that produced by autografts [1]. 
MATERIALS AND METHODS 
  Ninety seven consecutive patients with benign and low 
grade malignant bone tumors and tumor-like conditions of 
bone, aged 12 to 75 years (35.2 years mean), underwent a 
total of 104 procedures between January 2000 and October 
2003. There were 53 females (50%) and 44 males (46%) 
Patients had pre-operative imaging studies that included ra-
diographs, computerized tomography, magnetic resonance 
imaging and bone scintigraphy when appropriate. Needle 
biopsies were performed pre-operatively in some patients, 
but most patients underwent an open biopsy at the time of 
definitive surgery to confirm the diagnosis. Tumors were 
classified as benign latent, benign aggressive, and low-grade 
malignant. 
  The microparticulate cortical bone allograft was prepared 
by the University of Miami Tissue Bank (Miami, FL) ac-
cording to a previously described method (7). This allograft 
was generated from a single donor. Freeze-dried cortical 
bone particles were less than 250 μm in maximum dimension 
and over 100 mm in minimum dimension. All bones from 
which allografts were prepared were excised and processed 
aseptically. The allografts were processed in compliance 
with Food and Drug Administration and American Associa-
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lograft was reconstituted with sterile saline (Fig. 1) or left in 
its original state, and packed or injected into the defect under 
fluoroscopy. The graft was injected percutaneously or 
packed through an open wound. 
 
Fig. (1). Cortical microparticulate allograft reconstituted with sa-
line. 
  Biplanar radiographs of the operated site were obtained 
at the time of surgery, and at 6 weeks, 3 months, 6 months 
and one year after the procedure. The patients were then fol-
lowed for up to 4 years. 
  In order to assess the incorporation of the bone graft, 
each radiograph was reviewed by two independent examin-
ers. The following parameters were evaluated: 1) Presence or 
absence of trabeculae within the grafted defect, 2) Overall 
bone density, 3) Quality of bone at the border of graft (de-
scribed as well defined, hazy or invisible), and 4) Bone den-
sity within the defect (described as same as, equal to, or less 
than adjacent normal bone). 
  Incorporation was said to be present if the border be-
tween graft and cavity was vague and trabeculae were pre-
sent at the interface. Consolidation was identified if the bor-
der between graft and cavity was not identifiable, trabeculae 
were present at the interface, and the density of bone graft 
was the same as that of the adjacent normal bone. Failure 
was determined to have occurred when a secondary opera-
tion to revise the primary bone graft procedure was needed 
or when there was no radiographic evidence of graft incorpo-
ration. The follow-up interval was defined as the period of 
time from the last operative intervention to the last clinical 
and radiographic evaluation. 
  In addition to the radiological data, variables analyzed 
included: patient age, gender, diagnosis, site of disease, de-
fect size, procedure performed, presence or absence of a pre-
operative fracture, and complications related to surgery. A 
notation was made about the type of defect, either open or 
closed. A closed defect was defined as a defect within bone 
with well contained graft whereas an open defect was gener-
ally located on the surface of bone and bordered only by 
periosteum or muscle. 
  Data was stored and collated on Microsoft Excel soft-
ware and then transferred to SPSS software for analysis. 
 
RESULTS 
  Diagnostic categories included: cystic (25), fibrous (15), 
chondroid (36), giant cell lesions (14), osteomyelitis (1), 
osteonecrosis (1), osseous tumor (3), lymphoma (1) and 
cavitary non-union (1) There were 65 benign latent lesions, 
27 benign aggressive tumors and 5 low-grade malignant tu-
mors. The most common sites of disease were distal femur, 
proximal tibia, proximal humerus, pelvis and distal tibia 
(Table 1). 
Table 1.  Anatomic Locations of Lesions 
 
Site Number  &  Percent 
Proximal femur  5 (5.2) 
Distal femur  33 (34%) 
Proximal tibia  18(18.6) 
Distal tibia  6 (6.2) 
Proximal humerus  8 (8.4) 
Distal humerus  3 ( 3.1 ) 
Proximal radius  1  (1) 
Distal radius  2 (2) 
Proximal ulna  1 (1) 
Distal ulna  2  (2) 
Phalanx 4  (4) 
Cuboid  1  (1) 
Calcaneus 1  (1) 
Pelvis 6  (6.2) 
Distal fibula  3 (3.1) 
Cuneiform 1  (1) 
Patella 1  (1) 
Clavicle 1  (1) 
 
  The mean defect size was 42.8 cm
3 (0.48 - 315.0 cm
3). 
There were 87 (89.7%) closed defects and 10 (10.3%) open 
defects. In all cases the tumor was curetted; in 44.5% a high 
speed burr was used, and in 45.5% phenol was applied to 
extend the margin of resection. The defect was filled with 
particulate cortical allograft in all cases. Instrumentation was 
used to stabilize the bone in 11% of cases. Thirteen (13.4%) 
of 97 patients had a pathologic fracture prior to treatment. 
  The rate of consolidation was 60%, from 6 weeks to 108 
weeks, and the rate of incorporation was 91%, from 4 to 68 
weeks. There was no statistically significant difference be-
tween osseous healing and diagnosis, defect size or site of 
disease. An example of a patient with a bone cavity filled 
with microparticulate graft is given in Fig. (2). 
  Eleven procedures, in eleven patients, were considered 
failures. There were seven patients with recurrent tumors; 
three with giant cell tumors, two with aneurysmal bone 
cysts, and one each with a fibroxanthoma and fibrous dys-
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Fig. (2). AP radiograph of femur of 23 year old male with an aneu-
rysmal bone cyst involving the subtrochanteric region of the femur 
following resection and allograft packing. Left: incorporation at 6 
weeks. Right: consolidation at 3 months. 
 
Table 2.  Patients with Tumor Recurrences 
 
Case  Age Tumor  Location  Previous  Surgery 
1  31  Giant cell tumor  Distal humerus  No 
2  51  Giant cell tumor  Distal radius  No 
3  62  Giant cell tumor  Distal tibia  Yes 
4  18  Aneurysmal bone cyst  Proximal radius  No 
5  14  Aneurysmal bone cyst  Distal tibia  No 
6 12  Fibroxanthoma  Distal  tibia  No 
7  44  Fibrous dysplasia  Proximal femur  Yes  
 
  The average time from the index procedure to tumor re-
currence was 9.7 months. All patients, but one underwent a 
secondary grafting procedure with satisfactory functional 
and oncologic outcomes. One patient with a giant cell tumor 
of the distal radius, in addition to having a recurrence, sus-
tained a closed fracture after the index procedure which 
healed with cast immobilization. In addition, this patient had 
a soft tissue recurrence following re-excision and grafting. 
She is free of tumor three years after the bone recurrence and 
two years six months after the soft tissue recurrence (Fig. 3). 
The defect is consolidated. 
  Another patient with a giant cell tumor of the distal tibia 
presented with a recurrence after an incomplete resection at 
an outside hospital. At the time of treatment for this recur-
rence, there was a 1 cm defect in the articular cartilage that 
was filled with a gel foam patch and packed with micropar-
ticulate bone allograft. The tumor recurred again after 14 
months. At that time, he underwent re-curetting with bone 
allograft and polymethylmethacrylate packing of the defect. 
He is free of tumor twenty months following treatment for 
the second recurrence. Finally, a 44 year old patient with 
fibrous dysplasia of the proximal femur and with long-
standing deformity of the proximal femur complained of 
persistent pain and inability to walk without assistive devices 
following curetting and allograft packing. This patient un-
derwent resection of the proximal femur and reconstruction 
with an un-cemented proximal femoral replacement. 
 
Fig. (3A). Post-operative AP radiograph of the wrist of a 51 year 
old woman with a giant cell tumor of the distal radius who under-
went extended curetting and allograft packing. There is extensive 
bone graft material in the soft tissue. 
 
 
Fig. (3B). AP radiograph of the same patient one year later with 
complete incorporation of the graft material and resorption of the 
graft in soft tissue. 
  Two patients had deep infections that required operative 
debridement and antibiotic therapy. In both patients, the in-
fection resolved and the graft was retained and subsequently 
consolidated. One patient had a cystic chondroblastoma of 
the calcaneus, and the other had a chondrosarcoma of the 
pelvis that was resected and instrumented with segmental 
pedicle screws and plates. In the later case, the allograft was 
used to fill a large defect between the residual sacrum and 
the ilium. 
  Two additional patients had prolonged drainage and re-
quired oral antibiotics. A third had a stitch abscess that re-
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  Two patients required re-operations, for a non-union of 
the femur in one case, and an acetabular fracture in another. 
The patient with the non-union presented with a large uni-
cameral bone cyst in the inter-trochanteric region of the hip 
with extension into the sub-trochanteric femur. In addition, 
he had a displaced pathologic fracture. This patient under-
went curetting and allograft bone packing and stabilization 
with a hip screw and side plate. Due to persistent pain and 
the radiographic presence of a failure to heal six months 
post-operatively, this patient underwent removal of the screw 
and side plate and antegrade intramedually nailing The uni-
cameral cyst was completely healed and the fracture united 8 
weeks following the revision procedure. In addition, a 77 
year old male, with a protrusio fracture of the pelvis, follow-
ing chemotherapy and radiation for a non-Hodgkin’s lym-
phoma of the hip, underwent total hip arthroplasty and aug-
mentation of the medial acetabular deficiency with micropar-
ticulate allograft. He subsequently developed a large medial 
wall acetabular fracture with a protrusio deformity for which 
he underwent acetabular cage reconstruction with a large 
structural allograft. 
  Finally, a 19 year old male with osteonecrosis of the 
proximal tibia developed regional pain syndrome after curet-
ting and allograft bone grafting of the defect. This resolved 
two years after the index procedure with non-operative pain 
management. 
DISCUSSION 
  Clinical results obtained in this study indicate that freeze-
dried particulate allografts can be safely used for filling of 
cavitary bone defects. 
  In this study, all allografts were freeze-dried and, during 
processing, the machine temperature was kept cooler than 
50
0C. The freeze-drying process, removal of fat and marrow 
elements and standardization of the milling to near exact 
particle size, resulted in a stronger compacted graft substrate 
that is more resistant to shear, the usual mode of mechanical 
failure [24, 25]. These reproducible osteoconductive and 
osteoinductive properties of the graft produce the uniform 
clinical results reported in this investigation. Osteoinductive 
and osteoconductive properties of these grafts were estab-
lished in laboratory studies [1] 
  Both benign and malignant tumors of bone present diag-
nostic and therapeutic challenges for the orthopaedic oncolo-
gist. The indications for surgical treatment of benign bone 
tumors and tumor-like lesions depends on the presence or 
absence of clinical symptoms, the anatomic location of the 
lesion, and its biological activity. Symptomatic lesions that 
progressively increase in size and demonstrate radiographic 
signs of aggressiveness such as deep endosteal scalloping, 
cortical destruction and periosteal new bone formation, 
should be considered for biopsy and surgical removal [8]. 
Despite advanced imaging techniques, including magnetic 
resonance imaging, fastidious attention to tumor treatment 
principles, and the availability of allogenic grafts and bone 
substitutes, control of tumor recurrence and osseous healing 
can be problematic. 
  Despite extended curetting and the application of phenol 
for patients with benign aggressive tumors, there were seven 
tumor recurrences in this series. In six of these patients, sal-
vage was achieved by appropriate surveillance and early 
intervention by repeated intralesional excision and allograft 
bone grafting. In the 11 patients with giant cell tumors, there 
were 3 recurrences (27%). O’Donnell [12] reported fifteen 
recurrent tumors in 60 patients (25%), and Malawer recorded 
eight recurrent tumors in 103 (7.9%) patients [26]. Although 
thorough curetting, cryosurgery and the use of a high speed 
burr extended the intralesional margin of resection these 
newer techniques have not eliminated the incidence of tumor 
recurrence. This highlights the fact that neither bone grafting 
nor the improvement in surgical techniques have solved this 
problem. 
  We considered the seven cases with tumor recurrence as 
failures. However, this is not altogether accurate since in six 
of these patients, treated with re-resection and bone grafting, 
bone incorporation was complete. Even two patients with 
deep infections retained and incorporated their grafts. In two 
cases results with allograft bone were not adequate. The first 
patient was an elderly man with a lymphoma who underwent 
chemotherapy and radiotherapy to the acetabulum. He sub-
sequently developed avascular necrosis and a protrusio de-
formity of the proximal femur. Despite the appearance of 
graft consolidation after total hip arthroplasty, the patient 
subsequently developed a fracture of the medial wall requir-
ing revision surgery with a structural allograft and a cage. 
Although a number of successful grafting procedures using 
allograft particulate bone have been performed in patients 
with deficient medial acetabular walls, radiotherapy in this 
patient more than likely inhibited bone remodeling. Al-
though the patient with fibrous dysplasia underwent internal 
fixation to augment the proximal femur after curetting and 
allograft packing, he continued to have pain that may have 
been more related to his disease than to structural insuffi-
ciency. When the oncologic results are separated from the 
reconstructive results, the later two cases and the two deep 
infections represent the only true failures of the use of the 
microparticulate bone allograft in the 97 patients included in 
this series. 
  In this study, the rate of consolidation was 60% (from 6 
to 108 weeks), and incorporation was observed in 91% (from 
4 to 68 weeks). In most cases, the short healing period made 
prolonged cast immobilization unnecessary. Internal fixation 
was used in only 11% of cases. The microparticulate graft 
was effective for both closed and open defects and residual 
graft in the adjacent soft tissue resorbed between 6 weeks 
and 3 months. The absence of donor morbidity and the rapid 
rate of incorporation, coupled with a low complication rate, 
make the microparticulate bone allograft an attractive alter-
native to autograft. The bone allograft composite used in the 
study facilitated rapid vascular in-growth. This rapid process 
of neo-vascularization and incorporation may explain the 
relative resistance of this graft material to peri-operative bac-
terial contamination and preservation of the graft in the face 
of deep infection. 
  The present study was performed with a limited objec-
tive. We wanted to find out if replacing autologous bone 
grafting in patients with cavitary defects following resection 
of tumors was a sound clinical procedure. It appears it is. 
Results with autografts are well known. Success rate as also 
high as it is with a present technique. With success rates as 
high as these comparisons have little to offer. The literature 
on the treatment of bone defects created by tumor ablation is 96    The Open Orthopaedics Journal, 2008, Volume 2  Temple and Malinin 
scant. Comparison of results obtained in the present study 
with those obtained with revision arthroplasty would fall 
short of the mark, as the procedures and the reasons for per-
forming operation are vastly different. 
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